ATE468862T1 - G-csf konjugate - Google Patents

G-csf konjugate

Info

Publication number
ATE468862T1
ATE468862T1 AT02760160T AT02760160T ATE468862T1 AT E468862 T1 ATE468862 T1 AT E468862T1 AT 02760160 T AT02760160 T AT 02760160T AT 02760160 T AT02760160 T AT 02760160T AT E468862 T1 ATE468862 T1 AT E468862T1
Authority
AT
Austria
Prior art keywords
csf
conjugates
lysine residue
polypeptide
conjugated
Prior art date
Application number
AT02760160T
Other languages
English (en)
Inventor
Torben Nissen
Kim Andersen
Christian Hansen
Jan Mikkelsen
Hans Schambye
Original Assignee
Maxygen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27222576&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE468862(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US09/904,196 external-priority patent/US6555660B2/en
Application filed by Maxygen Inc filed Critical Maxygen Inc
Application granted granted Critical
Publication of ATE468862T1 publication Critical patent/ATE468862T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT02760160T 2001-07-11 2002-07-10 G-csf konjugate ATE468862T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US09/904,196 US6555660B2 (en) 2000-01-10 2001-07-11 G-CSF conjugates
DKPA200200447 2002-03-22
DKPA200200708 2002-05-08
PCT/DK2002/000482 WO2003006501A2 (en) 2001-07-11 2002-07-10 G-csf conjugates

Publications (1)

Publication Number Publication Date
ATE468862T1 true ATE468862T1 (de) 2010-06-15

Family

ID=27222576

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02760160T ATE468862T1 (de) 2001-07-11 2002-07-10 G-csf konjugate

Country Status (16)

Country Link
US (4) US7696153B2 (de)
EP (1) EP1425304B9 (de)
JP (1) JP4444652B2 (de)
KR (1) KR100961859B1 (de)
AT (1) ATE468862T1 (de)
AU (1) AU2002325819B2 (de)
BR (1) BR0211071A (de)
CA (1) CA2452582C (de)
DE (1) DE60236522D1 (de)
HU (1) HUP0400466A3 (de)
IL (1) IL159524A0 (de)
MX (1) MXPA04000231A (de)
NO (1) NO20040093L (de)
NZ (1) NZ530545A (de)
PL (1) PL371781A1 (de)
WO (1) WO2003006501A2 (de)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7173003B2 (en) 2001-10-10 2007-02-06 Neose Technologies, Inc. Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
US7214660B2 (en) 2001-10-10 2007-05-08 Neose Technologies, Inc. Erythropoietin: remodeling and glycoconjugation of erythropoietin
US20070026485A1 (en) 2003-04-09 2007-02-01 Neose Technologies, Inc. Glycopegylation methods and proteins/peptides produced by the methods
US9005625B2 (en) 2003-07-25 2015-04-14 Novo Nordisk A/S Antibody toxin conjugates
EP1673387B1 (de) * 2003-10-10 2010-09-15 Novo Nordisk A/S Il-21-derivate
US20060228331A1 (en) * 2003-10-10 2006-10-12 Novo Nordisk A/S IL-21 Derivatives and variants
US7220407B2 (en) 2003-10-27 2007-05-22 Amgen Inc. G-CSF therapy as an adjunct to reperfusion therapy in the treatment of acute myocardial infarction
US20080305992A1 (en) 2003-11-24 2008-12-11 Neose Technologies, Inc. Glycopegylated erythropoietin
US20070254836A1 (en) * 2003-12-03 2007-11-01 Defrees Shawn Glycopegylated Granulocyte Colony Stimulating Factor
EP1586334A1 (de) * 2004-04-15 2005-10-19 TRASTEC scpa G-CSF Konjugate mit PEG
EP2586456B1 (de) 2004-10-29 2016-01-20 ratiopharm GmbH Umformung und GlycoPEGylierung des Fibroblastenwachstumsfaktors (FGF)
US20060153799A1 (en) 2004-11-05 2006-07-13 Northwestern University Use of SCF and G-CSF in the treatment of cerebral ischemia and neurological disorders
JP2006137678A (ja) * 2004-11-10 2006-06-01 Shionogi & Co Ltd インターロイキン−２組成物
AU2006203792B2 (en) 2005-01-10 2011-11-03 Ratiopharm Gmbh Glycopegylated Granulocyte Colony Stimulating Factor
EP2386571B1 (de) 2005-04-08 2016-06-01 ratiopharm GmbH Zusammensetzungen und Verfahren zur Herstellung von Glycosylierungsmutanten eines Proteaseresistenten menschlichen Wachstumshormons
ATE500847T1 (de) 2005-06-01 2011-03-15 Maxygen Inc Pegylierte g-csf-polypeptide und herstellungsverfahren dafür
KR100694994B1 (ko) 2005-06-13 2007-03-14 씨제이 주식회사 사람 과립구 콜로니 형성인자 동종체
US20070105755A1 (en) 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
EP1948676A4 (de) * 2005-10-27 2011-05-25 Peptron Co Ltd Biologisch wirksames substanz-protein-konjugat und stabilisierung einer biologisch aktiven substanz damit
WO2007056191A2 (en) 2005-11-03 2007-05-18 Neose Technologies, Inc. Nucleotide sugar purification using membranes
US20080242607A1 (en) 2006-07-21 2008-10-02 Neose Technologies, Inc. Glycosylation of peptides via o-linked glycosylation sequences
MY150687A (en) 2006-07-21 2014-02-28 Femalon S P R L Assay and kit for predicting implantation success in assisted fertilisation
US9176145B2 (en) 2006-07-21 2015-11-03 Femalon S.P.R.L. Kit for predicting implantation success in assisted fertilization
ES2542146T3 (es) * 2006-07-31 2015-07-31 Novo Nordisk A/S Insulinas extendidas PEGiladas.
ITMI20061624A1 (it) * 2006-08-11 2008-02-12 Bioker Srl Mono-coniugati sito-specifici di g-csf
US20100075375A1 (en) 2006-10-03 2010-03-25 Novo Nordisk A/S Methods for the purification of polypeptide conjugates
EA017770B1 (ru) 2007-04-03 2013-03-29 Биодженерикс Аг Способы лечения с использованием гликопэгилированного g-csf
CN101778859B (zh) 2007-06-12 2014-03-26 诺和诺德公司 改良的用于生产核苷酸糖的方法
CN103497246B (zh) 2008-02-27 2016-08-10 诺沃—诺迪斯克有限公司 缀合的因子viii分子
JOP20190083A1 (ar) 2008-06-04 2017-06-16 Amgen Inc بولي ببتيدات اندماجية طافرة لـfgf21 واستخداماتها
EP2344203A2 (de) * 2008-09-19 2011-07-20 Maxygen, Inc. Verfahren zur behandlung von strahleninduzierter neutropenie durch verabreichung einer multi-pegylierten variante des granulozytenkolonie-stimulierenden faktors (g-csf)
CA2739615C (en) 2008-10-10 2017-12-05 Amgen Inc. Fgf21 mutants comprising polyethylene glycol and uses thereof
CA2760674A1 (en) 2009-05-05 2010-11-11 Amgen Inc. Fgf21 mutants and uses thereof
AU2010246108B2 (en) 2009-05-05 2014-10-23 Amgen Inc. FGF21 mutants and uses thereof
JP2012530493A (ja) * 2009-06-17 2012-12-06 アムジエン・インコーポレーテツド キメラポリペプチドおよびその使用
CA2781099A1 (en) 2009-11-17 2011-05-26 Janssen Biotech, Inc. Improved bacterial membrane protein secrection
WO2011068893A1 (en) 2009-12-02 2011-06-09 Amgen Inc. BINDING PROTEINS THAT BIND TO HUMAN FGFR1C, HUMAN β-KLOTHO AND BOTH HUMAN FGFR1C AND HUMANβ-KLOTHO
UA109888C2 (uk) 2009-12-07 2015-10-26 ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ
ES2639398T3 (es) 2010-03-04 2017-10-26 Pfenex Inc. Método para producir proteína de interferón recombinante soluble sin desnaturalización
NZ603033A (en) 2010-04-01 2014-06-27 Pfenex Inc Methods for g-csf production in a pseudomonas host cell
CA2796055A1 (en) 2010-04-15 2011-10-20 Amgen Inc. Human fgf receptor and .beta.-klotho binding proteins
US9320777B2 (en) 2011-05-13 2016-04-26 Bolder Biotechnology, Inc. Methods and use of growth hormone supergene family protein analogs for treatment of radiation exposure
WO2016013725A1 (ko) * 2014-07-23 2016-01-28 주식회사 이큐스앤자루 과립구 콜로니 자극인자 변이 단백질 또는 이의 트랜스페린 융합 단백질을 유효성분으로 포함하는 약학적 조성물
KR101623906B1 (ko) 2014-07-23 2016-05-24 주식회사 이큐스앤자루 과립구 콜로니 자극인자 변이 단백질 또는 이의 트랜스페린 융합 단백질을 유효성분으로 포함하는 약학적 조성물
CN113234138A (zh) * 2014-08-11 2021-08-10 德里尼亚公司 选择性地活化调节性t细胞用于治疗自身免疫病的修饰的il-2变体
DK3192524T3 (da) 2014-09-10 2022-02-14 Kringle Pharma Inc Hgf præparat egnet til behandling af neurologiske lidelser
CN107949565A (zh) * 2015-06-11 2018-04-20 安姆生物制药有限责任公司 聚乙二醇化粒细胞集落刺激因子(gcsf)
US11229683B2 (en) 2015-09-18 2022-01-25 Bolder Biotechnology, Inc. Hematopoietic growth factor proteins and analogs thereof and angiotensin converting enzyme inhibitors for treatment of radiation exposure
US20170204154A1 (en) 2016-01-20 2017-07-20 Delinia, Inc. Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
SG11201903882VA (en) 2016-11-08 2019-05-30 Delinia Inc Il-2 variants for the treatment of autoimmune diseases

Family Cites Families (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3209596C2 (de) * 1982-03-17 1985-10-03 Uni-Cardan Ag, 5200 Siegburg Gleichlaufdrehgelenk
WO1985000817A1 (en) 1983-08-10 1985-02-28 Amgen Microbial expression of interleukin ii
JPS61227526A (ja) 1984-07-25 1986-10-09 Chugai Pharmaceut Co Ltd 新規なコロニー刺激因子
EP0215126B1 (de) 1985-02-08 1991-07-31 Chugai Seiyaku Kabushiki Kaisha Menschlicher granuloxcyt-kolonie-stimulierungsfaktor
US6004548A (en) 1985-08-23 1999-12-21 Amgen, Inc. Analogs of pluripotent granulocyte colony-stimulating factor
JPS63500636A (ja) 1985-08-23 1988-03-10 麒麟麦酒株式会社 多分化能性顆粒球コロニー刺激因子をコードするｄｎａ
US4810643A (en) 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
JPS6263335A (ja) 1985-09-13 1987-03-20 Fuji Photo Film Co Ltd 化学反応情報の処理方法
EP0220520B1 (de) 1985-09-30 1991-09-18 Chugai Seiyaku Kabushiki Kaisha Menschlicher Granulozyten-Colony stimulierender Faktor
DE3771509D1 (de) 1986-01-22 1991-08-29 Chugai Pharmaceutical Co Ltd Pharmazeutischer stoff fuer die foerderung der wiederherstellung der haematopoietischen faehigkeit.
US4908773A (en) 1987-04-06 1990-03-13 Genex Corporation Computer designed stabilized proteins and method for producing same
DK203187A (da) 1986-04-22 1987-10-23 Immunex Corp Human g-csf proteinekspression
JPH01500483A (ja) 1986-08-11 1989-02-23 シタス　コーポレイション Ｇ‐ｃｓｆ及びそのミューテインの発現
US4704692A (en) 1986-09-02 1987-11-03 Ladner Robert C Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US5214132A (en) 1986-12-23 1993-05-25 Kyowa Hakko Kogyo Co., Ltd. Polypeptide derivatives of human granulocyte colony stimulating factor
US5714581A (en) 1986-12-23 1998-02-03 Kyowa Hakko Kogyo Co., Ltd. Polypeptide derivatives of human granulocyte colony stimulating factor
DK174044B1 (da) 1986-12-23 2002-05-06 Kyowa Hakko Kogyo Kk Polypeptid afledt fra human granulocytkolonistimulerende faktor, og fremgangsmåde til fremstilling deraf, DNA kodende for nævnte polypeptid, rekombinant plasmid indeholdende nævnte DNA, og mikroorganismer indeholdende nævnte rekombinante plasmid.......
US5362853A (en) 1986-12-23 1994-11-08 Kyowa Hakko Kogyo Co., Ltd. Polypeptide derivatives of human granulocyte colony stimulating factor
US4853871A (en) 1987-04-06 1989-08-01 Genex Corporation Computer-based method for designing stablized proteins
GB2213821B (en) 1987-12-23 1992-01-02 British Bio Technology Synthetic human granulocyte colony stimulating factor gene
US4904584A (en) 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
CA1340810C (en) 1988-03-31 1999-11-02 Motoo Yamasaki Polypeptide derivatives of human granulocyte colony stimulating factor
ES2063783T3 (es) 1988-06-03 1995-01-16 Chugai Pharmaceutical Co Ltd Factor de cristalino humano de estimulacion de colonias de granulocitos y procedimiento para su preparacion.
US5025388A (en) 1988-08-26 1991-06-18 Cramer Richard D Iii Comparative molecular field analysis (CoMFA)
US5218092A (en) 1988-09-29 1993-06-08 Kyowa Hakko Kogyo Co., Ltd. Modified granulocyte-colony stimulating factor polypeptide with added carbohydrate chains
US5349052A (en) 1988-10-20 1994-09-20 Royal Free Hospital School Of Medicine Process for fractionating polyethylene glycol (PEG)-protein adducts and an adduct for PEG and granulocyte-macrophage colony stimulating factor
US5104651A (en) 1988-12-16 1992-04-14 Amgen Inc. Stabilized hydrophobic protein formulations of g-csf
ATE135370T1 (de) 1988-12-22 1996-03-15 Kirin Amgen Inc Chemisch modifizierte granulocytenkolonie erregender faktor
US6166183A (en) 1992-11-30 2000-12-26 Kirin-Amgen, Inc. Chemically-modified G-CSF
US20020177688A1 (en) 1988-12-22 2002-11-28 Kirin-Amgen, Inc., Chemically-modified G-CSF
US5122614A (en) 1989-04-19 1992-06-16 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
US5109119A (en) 1989-06-06 1992-04-28 Schering Corporation Crystalline r-h-gm-csf and method
IE66494B1 (en) 1989-09-26 1996-01-10 Immunex Corp Granulocyte-colony stimulating factor receptors
US5265030A (en) 1990-04-24 1993-11-23 Scripps Clinic And Research Foundation System and method for determining three-dimensional structures of proteins
GB9107846D0 (en) 1990-04-30 1991-05-29 Ici Plc Polypeptides
US5399345A (en) 1990-05-08 1995-03-21 Boehringer Mannheim, Gmbh Muteins of the granulocyte colony stimulating factor
DE4014750A1 (de) 1990-05-08 1991-11-14 Boehringer Mannheim Gmbh Muteine des granulozyten-stimulierenden faktors (g-csf)
JP3249147B2 (ja) 1990-06-01 2002-01-21 キリン−アムジエン・インコーポレーテツド 生理活性蛋白含有経口製剤
IE912365A1 (en) 1990-07-23 1992-01-29 Zeneca Ltd Continuous release pharmaceutical compositions
EP0546124B2 (de) 1990-08-29 2003-04-23 Genetics Institute, LLC Aus mehreren domänen bestehende hämatopoese-stimulatoren
US5124297A (en) 1990-12-07 1992-06-23 Amoco Corporation Olefin polymerization and copolymerization catalyst
DE4105480A1 (de) 1991-02-21 1992-08-27 Boehringer Mannheim Gmbh Verbesserte aktivierung von rekombinanten proteinen
GB2253852B (en) 1991-02-26 1995-03-22 Ici Plc Vector for expression of heterologous polypeptide comprising inducible selection system
US5157736A (en) 1991-04-19 1992-10-20 International Business Machines Corporation Apparatus and method for optical recognition of chemical graphics
US5506107A (en) 1991-05-10 1996-04-09 Genentech, Inc. Selecting ligand agonists and antagonists
AU2408292A (en) 1991-07-11 1993-02-11 Regents Of The University Of California, The A method to identify protein sequences that fold into a known three-dimensional structure
US5386507A (en) 1991-07-18 1995-01-31 Teig; Steven L. Computer graphics system for selectively modelling molecules and investigating the chemical and physical properties thereof
US5281698A (en) 1991-07-23 1994-01-25 Cetus Oncology Corporation Preparation of an activated polymer ester for protein conjugation
WO1993005169A1 (en) 1991-08-30 1993-03-18 Fred Hutchinson Cancer Research Center Hybrid cytokines
JP2638359B2 (ja) 1991-11-26 1997-08-06 富士通株式会社 分子動力学法の拘束条件作成装置
ATE195553T1 (de) 1992-06-09 2000-09-15 Chiron Corp Kristallisierung von m-csf
ZA933926B (en) 1992-06-17 1994-01-03 Amgen Inc Polyoxymethylene-oxyethylene copolymers in conjuction with blomolecules
US6153183A (en) 1992-11-24 2000-11-28 G. D. Searle & Company Co-administration of interleukin-3 mutant polypeptides with CSF's or cytokines for multi-lineage hematopoietic cell production
JPH08503489A (ja) 1992-11-24 1996-04-16 ジー．ディー．サール アンド カンパニー インターロイキン−３（ｉｌ−３）突然変異ポリペプチド
US5772992A (en) 1992-11-24 1998-06-30 G.D. Searle & Co. Compositions for co-administration of interleukin-3 mutants and other cytokines and hematopoietic factors
US6057133A (en) 1992-11-24 2000-05-02 G. D. Searle Multivariant human IL-3 fusion proteins and their recombinant production
US5738849A (en) 1992-11-24 1998-04-14 G. D. Searle & Co. Interleukin-3 (IL-3) variant fusion proteins, their recombinant production, and therapeutic compositions comprising them
US5424963A (en) 1992-11-25 1995-06-13 Photon Research Associates, Inc. Molecular dynamics simulation method and apparatus
US5581476A (en) 1993-01-28 1996-12-03 Amgen Inc. Computer-based methods and articles of manufacture for preparing G-CSF analogs
JP2720140B2 (ja) * 1993-02-03 1998-02-25 日東化学工業株式会社 フェニル基を有する光学活性α−ヒドロキシカルボン酸の製造法
US6245900B1 (en) 1994-02-23 2001-06-12 Kyowa Hakko Kogyo Co., Ltd. Platelet production promoting agent
US5635599A (en) 1994-04-08 1997-06-03 The United States Of America As Represented By The Department Of Health And Human Services Fusion proteins comprising circularly permuted ligands
US5576941A (en) * 1994-08-10 1996-11-19 York Technologies, Inc. Modular power supply system
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US6254870B1 (en) 1995-02-03 2001-07-03 G. D. Searle & Co. Thrombopoietin: IL-3 fusion protein
US6017523A (en) 1995-06-06 2000-01-25 G.D. Searle & Co. Therapeutic methods employing mutant human interleukin-3 (IL-3) polypeptides
SE9503380D0 (sv) * 1995-09-29 1995-09-29 Pharmacia Ab Protein derivatives
JPH11510062A (ja) 1995-10-05 1999-09-07 ジー．ディー．サール アンド カンパニー 多機能性造血受容体アゴニスト
US6066318A (en) 1995-10-05 2000-05-23 G.D. Searle & Co. Multi-functional hematopoietic fusion proteins between sequence rearranged C-MPL receptor agonists and other hematopoietic factors
JP2000513924A (ja) 1995-10-05 2000-10-24 ジー．ディー．サール アンド カンパニー 新規ｃ−ｍｐｌ受容体アゴニスト
US6100070A (en) 1995-10-05 2000-08-08 G. D. Searle & Co. G-CSF receptor agonists
US6660257B1 (en) 1996-10-25 2003-12-09 Pharmacia Corporation Circular permuteins of flt3 ligand
BR9713668A (pt) 1996-10-25 2000-03-08 Searle & Co Agonistas de receptores hematopoiéticos quiméricos multifuncionais
US5969105A (en) 1996-10-25 1999-10-19 Feng; Yiqing Stem cell factor receptor agonists
NZ337911A (en) 1997-04-11 2001-04-27 G flt3 ligand chimeric proteins
DE69841682D1 (de) 1997-06-06 2010-07-08 Kyowa Hakko Kirin Co Ltd Chemisch modifizierte polypeptide
US5985263A (en) 1997-12-19 1999-11-16 Enzon, Inc. Substantially pure histidine-linked protein polymer conjugates
KR100622796B1 (ko) 1998-04-28 2006-09-13 어플라이드 리서치 시스템스 에이알에스 홀딩 엔.브이. 폴리올-ｉｆｎ-베타 공액체
US6451986B1 (en) * 1998-06-22 2002-09-17 Immunex Corporation Site specific protein modification
WO2000018905A1 (en) 1998-09-25 2000-04-06 G.D. Searle & Co. Method of producing permuteins by scanning permutagenesis
US6420339B1 (en) 1998-10-14 2002-07-16 Amgen Inc. Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility
JP2000319298A (ja) 1999-03-04 2000-11-21 Seibutsu Bunshi Kogaku Kenkyusho:Kk 蛋白質複合体の結晶、構造座標、及び構造座標の使用
KR100356140B1 (ko) 1999-07-08 2002-10-19 한미약품공업 주식회사 인간 과립구 콜로니 자극인자 변이체 및 이의 생산 방법
US6831158B2 (en) * 2000-01-10 2004-12-14 Maxygen Holdings Ltd. G-CSF conjugates
HUP0203751A3 (en) * 2000-01-10 2005-01-28 Maxygen Holdings Ltd Redwood C G-csf conjugates
US6646110B2 (en) 2000-01-10 2003-11-11 Maxygen Holdings Ltd. G-CSF polypeptides and conjugates
US6555660B2 (en) * 2000-01-10 2003-04-29 Maxygen Holdings Ltd. G-CSF conjugates
WO2002020751A2 (en) 2000-09-07 2002-03-14 Eli Lilly And Company Hyperglycosylated polypeptides
DE60125381T2 (de) 2000-09-08 2007-04-12 Massachusetts Institute Of Technology, Cambridge Zusammensetzungen und verfahren mit analogen von g-csf
GB0022877D0 (en) 2000-09-18 2000-11-01 Isis Innovation Analogues
US20020142964A1 (en) 2000-11-02 2002-10-03 Nissen Torben Lauesgaard Single-chain polypeptides
EP1334127A1 (de) * 2000-11-02 2003-08-13 Maxygen Aps Einzelkette multimere polypeptide

Also Published As

Publication number Publication date
US7550566B2 (en) 2009-06-23
NO20040093L (no) 2004-03-09
BR0211071A (pt) 2004-12-21
KR20040084884A (ko) 2004-10-06
JP4444652B2 (ja) 2010-03-31
US7696153B2 (en) 2010-04-13
MXPA04000231A (es) 2004-05-04
KR100961859B1 (ko) 2010-06-09
CA2452582A1 (en) 2003-01-23
DE60236522D1 (de) 2010-07-08
AU2002325819B2 (en) 2008-06-19
WO2003006501A3 (en) 2004-03-25
EP1425304B1 (de) 2010-05-26
WO2003006501A2 (en) 2003-01-23
JP2005506317A (ja) 2005-03-03
EP1425304A2 (de) 2004-06-09
EP1425304B9 (de) 2010-09-08
NZ530545A (en) 2006-10-27
HUP0400466A2 (hu) 2005-01-28
US20060286068A1 (en) 2006-12-21
US7550565B2 (en) 2009-06-23
IL159524A0 (en) 2004-06-01
US20070010660A1 (en) 2007-01-11
US20110020266A1 (en) 2011-01-27
HUP0400466A3 (en) 2006-01-30
PL371781A1 (en) 2005-06-27
CA2452582C (en) 2013-01-22
US20060286069A1 (en) 2006-12-21

Similar Documents

Publication Publication Date Title
ATE468862T1 (de) G-csf konjugate
EA004789B9 (ru) Полимерные конъюгаты бета-1а-интерферона и их использование
DK1180121T3 (da) Langtidsvirkende insulinotrope peptider
MXPA03011284A (es) Mezclas de conjugados de farmaco de insulina-oligomero que comprenden polialquilenglicol, usos de los mismos y metodos para eleaborar los mismos.
BE2013C033I2 (de)
BR9910251A (pt) Estimulação hematopoiética
PL2049566T3 (pl) Swoiste dla miejsca monokoniugaty G-CSF
PT786257E (pt) Variantes de glicosilacao do activador de plasminogenio tissular com propriedades terapeuticas meloradas
HK1074855A1 (en) Glycoprotein synthesis
ATE399020T1 (de) Erythropoietin reduziert die chemotherapiebedingte in-vivo-toxizität
SG149685A1 (en) Polymer conjugates of neublastin and methods of using same
NO984052L (no) Rekombinante, adenovirale vektorer for human tumorgenterapi
CA2373252A1 (en) Long lasting anti-angiogenic peptides
IL130526A0 (en) Novel anti-allergenic agents

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties